You can also read the IBTA e-News July 2020 edition in full online here.
Some of the highlights from this month's round-up:
- Research published in Cancer Discovery has suggested that a new class of drug, PAR glycohydrolase (PARG) inhibitors, may be effective for gliomas that carry the IDH mutation.
- According to a paper published in Scientific Reports, a team of researchers from Australia has completed long-term animal trials of personalised microbeam radiation therapy (MRT) for brain tumours. MRT involves targeting tumour tissue with ultra-high dose rate X-rays, produced in microscopically thin beams via a particle accelerator (termed a synchrotron).
- A next generation sequencing technology called single-cancer cell RNA sequencing has been used to analyse the genetic material in 53,586 adult glioblastoma cells alongside 22,637 normal human brain cells, to reveal the genetic ‘roadmap’ for how glioblastoma tumours develop from a single cancer cell type.
- Published in Cell Reports, a team of researchers has analysed 100 patient glioblastoma tumour samples to create a comprehensive ‘atlas’, capable of predicting which drug treatment(s) are likely to have most effect.
- Novocure has announced that the first patient has been enrolled in a phase 2 pilot trial (EF-33) testing a high-intensity version of Tumor Treating Fields (TTF) in recurrent glioblastoma. To increase field intensity in the Optune device for this trial, Novocure designed high-intensity arrays with 14 ceramic discs each (compared to nine in the existing model).
- The Brain Tumour Charity (UK) and Meningioma UK, are to merge, the two charities have announced in a news release.
- A paper published in the journal Cell documents a suite of assessments and experiments examining the microscopic and molecular changes that occur in the tissue immediately surrounding a brain tumour (termed the brain tumour microenvironment).
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.